Avalo Therapeutics (NASDAQ:AVTX) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Avalo Therapeutics (NASDAQ:AVTX) from a hold rating to a sell rating in a research report report published on Saturday.

A number of other research firms have also recently issued reports on AVTX. Citizens Jmp lowered their price objective on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a research report on Thursday, May 14th. Guggenheim set a $48.00 price target on shares of Avalo Therapeutics and gave the company a “buy” rating in a report on Friday. Leerink Partners started coverage on shares of Avalo Therapeutics in a research note on Monday, July 6th. They issued an “outperform” rating and a $38.00 price objective for the company. Mizuho raised their price objective on shares of Avalo Therapeutics from $39.00 to $45.00 and gave the stock an “outperform” rating in a report on Thursday, May 14th. Finally, HC Wainwright decreased their target price on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Friday. Thirteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $45.10.

Avalo Therapeutics Stock Down 2.0%

Shares of AVTX opened at $18.32 on Friday. The stock’s 50-day moving average price is $17.26 and its 200 day moving average price is $16.29. The firm has a market capitalization of $969.13 million, a price-to-earnings ratio of -4.19 and a beta of 0.80. Avalo Therapeutics has a 12-month low of $8.29 and a 12-month high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). Equities research analysts expect that Avalo Therapeutics will post -2.58 EPS for the current year.

Insider Buying and Selling

In related news, insider Mittie Doyle sold 1,450 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $18.00, for a total value of $26,100.00. Following the sale, the insider owned 51,776 shares of the company’s stock, valued at $931,968. The trade was a 2.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.46% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Orbimed Advisors LLC lifted its holdings in Avalo Therapeutics by 39.5% during the 3rd quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after purchasing an additional 382,300 shares during the last quarter. Affinity Asset Advisors LLC grew its stake in Avalo Therapeutics by 27.6% during the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company’s stock worth $20,019,000 after buying an additional 289,786 shares during the last quarter. Nantahala Capital Management LLC increased its holdings in shares of Avalo Therapeutics by 24.1% during the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock worth $15,697,000 after buying an additional 240,000 shares in the last quarter. Caligan Partners LP raised its stake in shares of Avalo Therapeutics by 5.8% in the fourth quarter. Caligan Partners LP now owns 881,533 shares of the company’s stock valued at $16,009,000 after acquiring an additional 48,200 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in shares of Avalo Therapeutics in the third quarter valued at approximately $10,390,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.